{"id":"azithromycin-ophthalmic-solution-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Eye irritation"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Ocular discomfort"},{"rate":null,"effect":"Blurred vision"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Azithromycin binds to the bacterial 50S ribosomal subunit and inhibits transpeptidation and translocation, preventing peptide bond formation and halting protein synthesis. When formulated as an ophthalmic solution, it achieves high local concentrations in ocular tissues to treat bacterial infections of the eye. The drug is bactericidal against a broad spectrum of gram-positive and gram-negative organisms commonly associated with ocular infections.","oneSentence":"Azithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby killing or stopping the growth of susceptible bacteria.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:40:28.172Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial conjunctivitis"},{"name":"Bacterial keratitis"}]},"trialDetails":[{"nctId":"NCT03162497","phase":"PHASE4","title":"Effect of Topical Azithromycin on Tear Film Thickness in Patients With Meibomian Gland Dysfunction","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2018-01-08","conditions":"Dry Eye Syndromes, Meibomian Gland Dysfunction","enrollment":23},{"nctId":"NCT01560962","phase":"NA","title":"Efficacy of Over the Counter (OTC) Povidone-Ioldine 5% for Treatment of Acute or Chronic Blepharitis","status":"TERMINATED","sponsor":"Southern California Institute for Research and Education","startDate":"2012-01","conditions":"Blepharitis","enrollment":100},{"nctId":"NCT03235141","phase":"PHASE1","title":"Local Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers","status":"UNKNOWN","sponsor":"Beijing Tongren Hospital","startDate":"2017-07-07","conditions":"Bacterial Conjunctivitis","enrollment":56},{"nctId":"NCT01721694","phase":"PHASE3","title":"Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection","status":"WITHDRAWN","sponsor":"Adapt Produtos Oftalmológicos Ltda.","startDate":"2012-12","conditions":"Ocular Inflammation, Infection Associated Blepharitis, Keratitis","enrollment":""},{"nctId":"NCT01089608","phase":"PHASE2","title":"Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2010-03","conditions":"Blepharitis","enrollment":93},{"nctId":"NCT01220258","phase":"PHASE2","title":"A Four Week, Open-Label Study of Azithromycin Ophthalmic Solution, 1% (P08641)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-11","conditions":"Posterior Blepharoconjunctivitis","enrollment":29},{"nctId":"NCT00105469","phase":"PHASE3","title":"Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-07","conditions":"Bacterial Conjunctivitis","enrollment":743},{"nctId":"NCT01269658","phase":"PHASE2","title":"A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle in Subjects With Blepharitis (P08636)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-12","conditions":"Blepharitis","enrollment":40},{"nctId":"NCT00894530","phase":"PHASE2","title":"The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-05","conditions":"Blepharitis","enrollment":314},{"nctId":"NCT00656539","phase":"PHASE4","title":"Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-04","conditions":"Blepharitis","enrollment":20},{"nctId":"NCT00629941","phase":"PHASE4","title":"Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-03","conditions":"Blepharitis","enrollment":25},{"nctId":"NCT01014078","phase":"PHASE4","title":"A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-10","conditions":"Dry Eye Disease","enrollment":112},{"nctId":"NCT00629980","phase":"PHASE4","title":"Safety and Efficacy Pilot Study of AzaSite® (Azithromycin) in Subjects With Blepharitis","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-02","conditions":"Blepharitis","enrollment":60},{"nctId":"NCT00892970","phase":"PHASE2","title":"The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Two-Week Treatment Period","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04","conditions":"Blepharitis","enrollment":313},{"nctId":"NCT00629590","phase":"PHASE4","title":"Safety and Efficacy Pilot Study of AzaSite (Azithromycin) in Subjects With Blepharitis","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-03","conditions":"Blepharitis","enrollment":20},{"nctId":"NCT01105624","phase":"PHASE4","title":"A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-03","conditions":"Contact Lens Dry Eye","enrollment":50},{"nctId":"NCT00564447","phase":"PHASE4","title":"Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy Volunteers","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-12","conditions":"Bacterial Infections, Eye Infections","enrollment":48},{"nctId":"NCT00575380","phase":"PHASE4","title":"Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-12","conditions":"Bacterial Infections, Eye Infections, Cataract Extraction","enrollment":116},{"nctId":"NCT00575367","phase":"PHASE4","title":"Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-03","conditions":"Bacterial Infections, Eye Infections","enrollment":37},{"nctId":"NCT00357383","phase":"PHASE1","title":"Study of the Ocular Safety After Repeated Instillations of T1225 1% or 1.5% Eye Drops in Healthy Volunteers","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2002-10","conditions":"Eye Infections, Bacterial","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Azithromycin Ophthalmic Solution, 1%","genericName":"Azithromycin Ophthalmic Solution, 1%","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Azithromycin Ophthalmic Solution, 1% is used to treat bacterial conjunctivitis, blepharitis, posterior blepharoconjunctivitis, bacterial infections, and eye infections. It is compared to other treatments such as Tobramycin in clinical studies for its efficacy and safety.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}